<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HEMANGEOL- propranolol hydrochloride solution </strong><br>Pierre Fabre Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use HEMANGEOL safely and effectively. See full prescribing information for HEMANGEOL. <br></span><span class="Bold"><span class="Bold"><br><span class="Bold"><span class="Bold">HEMANGEOL<span class="Sup">®</span></span></span></span>(propranolol hydrochloride oral solution) </span><br><span class="Bold">Initial U.S. Approval: 1967<br><br></span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">HEMANGEOL oral solution is a beta-adrenergic blocker indicated for the treatment of proliferating infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> requiring systemic therapy. (<a href="#LINK_2c6119e9-0c5a-4dec-9518-14c689473375">1</a>)    </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li>Initiate treatment at ages 5 weeks to 5 months. (<a href="#LINK_5674b43d-d629-496f-a775-5302c56cd41f">2</a>)</li>
<li>Starting dose is 0.15 mL/kg (0.6 mg/kg) twice daily. After 1 week, increase dose to 0.3 mL/kg (1.1 mg/kg) twice daily. After 2 weeks, increase to a maintenance dose of 0.4 mL/kg (1.7 mg/kg) twice daily. (<a href="#LINK_5674b43d-d629-496f-a775-5302c56cd41f">2</a>) 
</li>
<li>Administer doses at least 9 hours apart during or after feeding. (<a href="#LINK_5674b43d-d629-496f-a775-5302c56cd41f">2</a>) 
</li>
<li>Readjust dose for changes in the child’s weight. (<a href="#LINK_5674b43d-d629-496f-a775-5302c56cd41f">2</a>) 
</li>
<li>Monitor heart rate and blood pressure for 2 hours after the first dose or increasing dose. (<a href="#LINK_5674b43d-d629-496f-a775-5302c56cd41f">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Oral solution: 4.28 mg/mL propranolol hydrochloride (<a href="#LINK_02469528-412a-4b2f-9f42-c9e9940ba21d">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disk">
<li>Premature infants with corrected age &lt;5 weeks (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a> )</li>
<li>Infants weighing less than 2 kg (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a>) 
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to propranolol or excipients (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a>) 
</li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> or history of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a>, <a href="#LINK_85b501cd-5aa3-4576-b24d-bda4fe7e80d1">5.3</a>, <a href="#LINK_600868c3-1069-4c28-ac12-ef4a2213d4bd">6</a>, <a href="#LINK_dcd36e08-fbb8-422e-a147-ba4aa1fe1e2d">10</a>, <a href="#LINK_4733d1df-e587-4abb-9982-2b5e21cc9565">17</a>) 
</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> (&lt;80 beats per minute), greater than first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">decompensated heart failure</span> (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a>, <a href="#LINK_3403a8fc-d7e0-4cc5-af9d-e9acc8902489">5.2</a>, <a href="#LINK_e8156160-3d92-4dcf-9d56-38176571d169">5.4</a>, <a href="#LINK_dcd36e08-fbb8-422e-a147-ba4aa1fe1e2d">10</a>, <a href="#LINK_4733d1df-e587-4abb-9982-2b5e21cc9565">17</a>) 
</li>
<li>Blood pressure &lt;50/30 mmHg (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a>, <a href="#LINK_3403a8fc-d7e0-4cc5-af9d-e9acc8902489">5.2</a>, <a href="#LINK_dcd36e08-fbb8-422e-a147-ba4aa1fe1e2d">10</a>, <a href="#LINK_4733d1df-e587-4abb-9982-2b5e21cc9565">17</a>) 
</li>
<li><span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span> (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: Administer during or after feeding. Do not use in patients who are not able to feed or are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a>, <a href="#LINK_7a4546a2-10bc-465d-abb9-374fb8ff54be">5.1</a>, <a href="#LINK_600868c3-1069-4c28-ac12-ef4a2213d4bd">6</a>, <a href="#LINK_dcd36e08-fbb8-422e-a147-ba4aa1fe1e2d">10</a>, <a href="#LINK_4733d1df-e587-4abb-9982-2b5e21cc9565">17</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a>, <a href="#LINK_3403a8fc-d7e0-4cc5-af9d-e9acc8902489">5.2</a>, <a href="#LINK_4733d1df-e587-4abb-9982-2b5e21cc9565">17</a>) 
</li>
<li><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>: Avoid use in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or lower <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span> (<a href="#LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325">4</a>, <a href="#LINK_85b501cd-5aa3-4576-b24d-bda4fe7e80d1">5.3</a>, <a href="#LINK_600868c3-1069-4c28-ac12-ef4a2213d4bd">6</a>, <a href="#LINK_dcd36e08-fbb8-422e-a147-ba4aa1fe1e2d">10</a>, <a href="#LINK_4733d1df-e587-4abb-9982-2b5e21cc9565">17</a>) 
</li>
<li>Increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in PHACE syndrome (<a href="#LINK_8b31df46-4178-484f-abb1-a9831bd0074d">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions to HEMANGEOL (occurring ≥ 10% of patients) were <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>, aggravated <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#LINK_600868c3-1069-4c28-ac12-ef4a2213d4bd">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact </span>P<span class="Bold">ierre Fabre Pharmaceuticals, Inc. at 1-855-PFPHARM (737-4276) or FDA at 1-800-FDA-1088 or <span class="Italics"><a href="#medwatch">www.fda.gov/medwatch</a>. </span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1    INDICATIONS AND USAGE</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2    DOSAGE AND ADMINISTRATION</span></a></h1>
<h1><a href="#section-3" class="toc"><span class="Bold">3    DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4    CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5    WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Increased Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in PHACE Syndrome</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6    ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7    DRUG INTERACTIONS</span></a></h1>
<h1><a href="#section-8" class="toc"><span class="Bold">8    USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.5" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10   OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11   DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12   CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.6 Drug Interactions</a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13   NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14   CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16   HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc"><span class="Bold">17   PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_2c6119e9-0c5a-4dec-9518-14c689473375"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1    INDICATIONS AND USAGE</span></h1>
<p class="First">HEMANGEOL oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> requiring systemic therapy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_5674b43d-d629-496f-a775-5302c56cd41f"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2    DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">Initiate treatment at ages 5 weeks to 5 months.</p>
<p>The recommended starting dose of HEMANGEOL is 0.15 mL/kg (0.6 mg/kg) (see Table 1) twice daily, taken at least 9 hours apart. After 1 week, increase the daily dose to 0.3 mL/kg (1.1 mg/kg) twice daily. After 2 weeks of treatment, increase the dose to 0.4 mL/kg (1.7 mg/kg) twice daily and maintain this for 6 months. Readjust the dose periodically as the child’s <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increases</span>.</p>
<p>To reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, administer HEMANGEOL orally during or right after a feeding. Skip the dose if the child is not eating or is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see <a href="#LINK_7a4546a2-10bc-465d-abb9-374fb8ff54be">Warnings and Precautions (5.1)</a>]</span>. </p>
<p>Monitor heart rate and blood pressure for 2 hours after HEMANGEOL initiation or dose increases <span class="Italics">[see <a href="#LINK_3403a8fc-d7e0-4cc5-af9d-e9acc8902489">Warnings and Precautions (5.2)</a>].</span></p>
<p>If <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> recur, treatment may be re-initiated <span class="Italics">[see </span><span class="Italics"><span class="Italics"><a href="#LINK_cc520742-f1bb-4b89-9c6f-e500e1fefc2c">Clinical Studies (14)</a></span>]</span>.</p>
<p>HEMANGEOL is supplied with an oral dosing syringe for administration. Administration directly into the child’s mouth is recommended. Nevertheless, if necessary, the product may be diluted in a small quantity of milk or fruit juice, given in a baby’s bottle.</p>
<p><span class="Bold">Table 1. Dose Titration According to Weight</span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center" valign="bottom"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">Week 1</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Week 2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Week 3 (maintenance)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Weight (kg)</span></p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Volume administered </span></p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Volume administered</span></p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Volume administered</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">twice a day</span> </td>
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">twice a day</span> </td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">twice a day</span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 to &lt;2.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.6 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.5 to &lt;3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 to &lt;3.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.9 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.5 to &lt;4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.1 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.4 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 to &lt;4.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.6 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.5 to &lt;5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.7 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.4 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.8 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5 to &lt;5.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5.5 to &lt;6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.7 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.2 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6 to &lt;6.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.9 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.8 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.4 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6.5 to &lt;7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.6 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7 to &lt;7.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.1 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.1 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.8 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7.5 to &lt;8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.1 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.3 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8 to &lt;8.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.4 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.2 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8.5 to &lt;9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.3 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.6 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.4 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9 to &lt;9.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.4 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.7 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.6 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9.5 to &lt;10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.4 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.9 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.8 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10 to &lt;10.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10.5 to &lt;11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.2 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.2 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11 to &lt;11.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.7 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.3 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.4 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11.5 to &lt;12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.7 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.5 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.6 mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12 to &lt;12.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.8 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3.6 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4.8 mL</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_02469528-412a-4b2f-9f42-c9e9940ba21d"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3    DOSAGE FORMS AND STRENGTHS</span></h1>
<p class="First">Oral solution: 4.28 mg/mL propranolol hydrochloride.</p>
<p>Alcohol, paraben and sugar free.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_f293dbb8-df75-4e8f-b249-cc4a877d7325"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4    CONTRAINDICATIONS</span></h1>
<p class="First">HEMANGEOL is contraindicated in the following conditions:</p>
<ul class="Disk">
<li>Premature infants with corrected age &lt; 5 weeks</li>
<li>Infants weighing less than 2 kg</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to propranolol or any of the excipients <span class="Italics">[see <a href="#LINK_1a8f1fbe-2c36-4ff1-b16f-3149c143fbae">Description (11)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> or history of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span></li>
<li>Heart rate &lt;80 beats per minute, greater than first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">decompensated heart failure</span></li>
<li>Blood pressure &lt;50/30 mmHg</li>
<li><span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_93ea7f0c-e4a9-461d-b14c-1d077b0a3b6c"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5    WARNINGS AND PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7a4546a2-10bc-465d-abb9-374fb8ff54be"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">HEMANGEOL prevents the response of endogenous catecholamines to correct <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and masks the adrenergic warning signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, particularly <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. HEMANGEOL can cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in children, especially when they are not feeding regularly or are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; withhold the dose under these conditions. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may present in the form of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. If a child has clinical signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, discontinue HEMANGEOL and call their health care provider immediately or take the child to the emergency room.</p>
<p>Concomitant treatment with corticosteroids may increase the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> <span class="Italics">[</span><span class="Italics">see </span><span class="Italics"><span class="Italics"><a href="#LINK_7a4546a2-10bc-465d-abb9-374fb8ff54be">Drug Interactions (7)</a></span>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3403a8fc-d7e0-4cc5-af9d-e9acc8902489"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">HEMANGEOL may cause or worsen <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In the studies of HEMANGEOL for infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> the mean decrease in heart rate was about 7 bpm with little effect on blood pressure. Monitor heart rate and blood pressure after treatment initiation or increase in dose. Discontinue treatment if severe (&lt;80 beats per minute) or symptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (systolic blood pressure &lt;50 mmHg) occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_85b501cd-5aa3-4576-b24d-bda4fe7e80d1"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></h2>
<p class="First">HEMANGEOL can cause <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>; do not use in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. Interrupt treatment in the event of a <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span> associated with <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e8156160-3d92-4dcf-9d56-38176571d169"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Sympathetic stimulation supports circulatory function in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, beta blockade may precipitate more severe failure. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8b31df46-4178-484f-abb1-a9831bd0074d"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Increased Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in PHACE Syndrome</h2>
<p class="First">By dropping blood pressure, HEMANGEOL may increase the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in PHACE syndrome patients with severe cerebrovascular anomalies. </p>
<p>Investigate infants with large facial infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> for potential <span class="product-label-link" type="condition" conceptid="321882" conceptname="Generalized atherosclerosis">arteriopathy</span> associated with PHACE syndrome prior to HEMANGEOL therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d480280c-b5e2-42c7-a1cd-7969a1aede74"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Beta-blockers will interfere with epinephrine used to treat serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_600868c3-1069-4c28-ac12-ef4a2213d4bd"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">6    ADVERSE REACTIONS</span></h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> and related events, like hypoglycemic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> <span class="Italics">[see <a href="#LINK_7a4546a2-10bc-465d-abb9-374fb8ff54be">Warnings and Precautions (5.1)</a>].</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> <span class="Italics">[see <a href="#LINK_85b501cd-5aa3-4576-b24d-bda4fe7e80d1">Warnings and Precautions (5.3)</a>].</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a024430b-6e55-4023-b15f-754891b7e5b3"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical<br>trials of a drug may not reflect the rates observed in clinical practice.</p>
<p><span class="Italics"><span class="Bold">Clinical Trials Experience with HEMANGEOL in Infants with proliferating infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span></span></span><br>In clinical trials for proliferating infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span>, the most frequently reported adverse reactions (&gt;10%) in infants treated with HEMANGEOL were <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>, aggravated <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span> such as <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4165112" conceptname="Bronchiolitis">bronchiolitis</span> associated with <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  Adverse reactions led to treatment discontinuation in fewer than 2% of treated patients.</p>
<p>Overall, 479 patients in the pooled safety population were exposed to study drug in the clinical study program (456 in placebo-controlled trials). A total of 424 patients were treated with HEMANGEOL at doses 1.2 mg/kg/day or 3.4 mg/kg/day for 3 or 6 months. Of these, 63% of patients were aged 91-150 days and 37% were aged 35-90 days at randomization.</p>
<p>The following table lists according to the dosage the most common adverse reactions (treatment-emergent adverse events with an incidence at least 3% greater on one of the two doses than on placebo).</p>
<p><span class="Bold">Table 2. Treatment-emergent adverse events occurring at least 3% more often on HEMANGEOL than on placebo</span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo<br>N=236</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">HEMANGEOL<br>1.2 mg/kg/day<br>N=200</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">HEMANGEOL<br>3.4 mg/kg/day<br>N=224</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep disorder</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5.9%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">17.5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">16.1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">Peripheral coldness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">Nightmare</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
</tbody>
</table>
<p>The following adverse events have been observed during clinical studies, with an incidence of less than 1%:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> Second degree atrioventricular <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, in a patient with underlying conduction disorder, required definitive treatment discontinuation <span class="Italics">[</span><span class="Italics">see </span><span class="Italics"><span class="Italics"><a href="#LINK_e8156160-3d92-4dcf-9d56-38176571d169">Warnings and Precautions</a></span><span class="Italics"><a href="#LINK_e8156160-3d92-4dcf-9d56-38176571d169">(</a></span><span class="Italics"><a href="#LINK_e8156160-3d92-4dcf-9d56-38176571d169">5.4</a></span><span class="Italics"><a href="#LINK_e8156160-3d92-4dcf-9d56-38176571d169">)</a></span>]</span>.</p>
<p><span class="Bold">Skin and subcutaneous tissue disorders: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span></p>
<p><span class="Bold">Investigations: </span>Decreased blood glucose, decreased heart rate</p>
<p><span class="Underline">Compassionate Use Program</span></p>
<p>More than 600 infants received HEMANGEOL in a compassionate use program (CUP). Mean age at treatment initiation was 3.6 months. Mean dose of HEMANGEOL was 2.2 mg/kg/day and mean treatment duration was 7.1 months. </p>
<p>The adverse reactions reported in the CUP were similar to the ADRs observed during clinical trials but some were more severe. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_760b9e37-88e7-4183-ba42-6165c48a65a2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of propranolol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<p>These adverse reactions are as follows:</p>
<p><span class="Bold">Blood and lymphatic system disorders: </span><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></p>
<p><span class="Bold">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span></p>
<p><span class="Bold">Skin and subcutaneous tissues disorders:</span> <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span> </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_0266c928-fa63-4e98-bae2-4d601418a42d"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7    DRUG INTERACTIONS</span></h1>
<p class="First">In the absence of specific studies in children, the drug interactions with propranolol are those known in adults. Consider both the infant’s medications and those of a nursing mother.</p>
<p><span class="Bold">Pharmacokinetic drug interactions</span></p>
<p><span class="Italics">Impact of co-administered drugs on propranolol: </span>CYP2D6, CYP1A2 or CYP2C19 inhibitors increase propranolol plasma concentration. CYP1A2 inducers (phenytoin, phenobarbital) or CYP2C19 inducers (rifampin) decrease propranolol plasma concentration when co-administered. </p>
<p><span class="Bold">Pharmacodynamic drug interactions</span></p>
<p><span class="Italics">Corticosteroids: </span>Patients on corticosteroids may be at increased risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> because of loss of the counter-regulatory cortisol response; monitor patients for signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_2f8c441d-229d-4fe7-be1c-7027ef0f0ee8"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">8    USE IN SPECIFIC POPULATIONS</span></h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_9abcc3c8-205e-4c8a-a584-383f3fe26dd4"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">HEMANGEOL is not intended to be prescribed to pregnant women <span class="Italics">[see </span><span class="Italics"><span class="Italics"><a href="#LINK_2c6119e9-0c5a-4dec-9518-14c689473375">Indications and Usage (</a></span><span class="Italics"><a href="#LINK_2c6119e9-0c5a-4dec-9518-14c689473375">1</a></span><span class="Italics"><a href="#LINK_2c6119e9-0c5a-4dec-9518-14c689473375">)</a></span>].</span></p>
<p>Pregnancy Category C.</p>
<p>In a series of reproductive and developmental toxicology studies, propranolol hydrochloride was given to rats by gavage or in the diet throughout pregnancy and lactation. At a dose of 150 mg/kg/day [which is about 2 times the maximum recommended human oral daily dose (MRHD) of 640 mg propranolol hydrochloride in adults on a body surface area basis], treatment was associated with embryotoxicity (reduced litter size and increased resorption rates) as well as neonatal toxicity (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>). Propranolol hydrochloride also was administered in the feed to rabbits throughout pregnancy and lactation at doses up to 150 mg/kg/day (about 5 times the maximum recommended human oral daily dose in adults). No evidence of embryo or neonatal toxicity was noted.</p>
<p>There are no adequate and well-controlled studies in pregnant women. <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">Intrauterine growth retardation</span>, small placentas, and congenital abnormalities have been reported in neonates whose mothers received propranolol during pregnancy. Neonates whose mothers received propranolol at parturition have exhibited <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Adequate facilities for monitoring such infants at birth should be available. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_bd665bbd-8bd3-4c87-958e-98794eadecc7"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">HEMANGEOL is not intended to be prescribed to breastfeeding women <span class="Italics">[see </span><span class="Italics"><span class="Italics"><a href="#LINK_2c6119e9-0c5a-4dec-9518-14c689473375">Indications and Usage (</a></span><span class="Italics"><a href="#LINK_2c6119e9-0c5a-4dec-9518-14c689473375">1</a></span><span class="Italics"><a href="#LINK_2c6119e9-0c5a-4dec-9518-14c689473375">)</a></span>].</span></p>
<p>Propranolol is excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_e7bdbc31-8543-4cc2-9461-7bf2d649ea83"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Of 460 infants with proliferating infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> requiring systemic therapy who were treated with HEMANGEOL starting at 5 weeks to 5 months of age, 60% had complete or nearly complete resolution of their <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> at Week 24 <span class="Italics">[see <a href="#LINK_cc520742-f1bb-4b89-9c6f-e500e1fefc2c">Clinical Studies (14)</a>].</span></p>
<p>Safety and effectiveness for infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> have not been established in pediatric patients greater than 1 year of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ddf60633-c658-4bca-b7b3-3ce0655e339d"></a><a name="section-8.4"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">There is no experience in infants with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span><span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c7a5cea7-d87d-47f6-a6c6-742891290f40"></a><a name="section-8.5"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">There is no experience in infants with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span><span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_dcd36e08-fbb8-422e-a147-ba4aa1fe1e2d"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">10   OVERDOSAGE</span></h1>
<p class="First">Few cases of propranolol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> were reported. For a single intake, the maximum dose was 20 mg/kg. Symptomatic cases featured <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, hypoglycemic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>/euphory/<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; for most cases, propranolol was maintained or reintroduced.</p>
<p>The toxicity of beta-blockers is an extension of their therapeutic effects:</p>
<p>- Cardiac symptoms of mild to moderate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> are decreased heart rate and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Atrioventricular blocks</span>, intraventricular conduction delays, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> can occur with more severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. </p>
<p>- <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> may develop particularly in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>- <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may develop and manifestations of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) may be masked by other clinical effects of beta-blocker toxicity.</p>
<p><span class="Italics">Support and treatment: </span>Place the patient on a cardiac monitor, and monitor vital signs, mental status and blood glucose. Give intravenous fluids for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and atropine for <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Glucagon then catecholamines should be considered if the patient does not respond appropriately to IV fluid. Isoproterenol and aminophylline may be used for <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.  </p>
<p>Propranolol is not dialyzable.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_1a8f1fbe-2c36-4ff1-b16f-3149c143fbae"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">11   DESCRIPTION</span></h1>
<p class="First">HEMANGEOL is an oral solution of propranolol that is alcohol free, paraben free and sugar free. Each mL of HEMANGEOL contains 4.28 mg of propranolol hydrochloride, USP equivalent to 3.75 mg of propranolol.</p>
<p>Propranolol hydrochloride is a synthetic beta-adrenergic receptor blocking agent chemically described as (2RS)1-[(1-methylethyl)amino]-3-(naphthalene-1-yloxy)-propan-2-ol hydrochloride. Its structural formula is shown in Figure 1:</p>
<p><img alt="Figure 1. Propranolol HCl structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-1.jpg"> </p>
<p><span class="Bold">Figure 1. Propranolol HCl Structure</span></p>
<p>Molecular formula: C<span class="Sub">16</span>H<span class="Sub">21</span>NO<span class="Sub">2</span>-HCl</p>
<p>Propranolol hydrochloride is a stable, white, crystalline solid with a molecular weight of 295.8. It is readily soluble in water and ethanol.</p>
<p>HEMANGEOL contains the following inactive ingredients: strawberry/vanilla flavorings, hydroxyethylcellulose, saccharin sodium, citric acid monohydrate, and water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_c76f3e69-6e51-4f0f-bf50-ff830ad12bb4"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">12   CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_58949e2b-513c-40c0-9f31-d4ab34ae970c"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of HEMANGEOL’s effects on infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> is not well understood. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_d8a14d57-51af-407f-a71b-c477314b03a0"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Propranolol is a nonselective beta-adrenergic receptor blocking agent possessing no other autonomic nervous system activity.  It specifically competes with beta-adrenergic receptor stimulating agents for available receptor sites.  When access to beta-receptor sites is blocked by propranolol, chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation are decreased proportionately.</p>
<p>Propranolol selectively blocks beta-adrenergic receptors, leaving alpha-adrenergic responses intact.  There are two well-characterized subtypes of beta receptors (beta1 and beta2); propranolol interacts with both subtypes equally.  Beta1-adrenergic receptors are found primarily in the heart.  Blockade of cardiac beta1-adrenergic receptors leads to a decrease in the activity of both normal and ectopic pacemaker cells and a decrease in A-V nodal conduction velocity.  Blockade of cardiac beta1-adrenergic receptors also decreases the myocardial force of contraction and may provoke cardiac decompensation in patients with minimal cardiac reserve.</p>
<p>Beta2-adrenergic receptors are found predominantly in smooth muscle-vascular, bronchial, gastrointestinal and genitourinary.  Blockade of these receptors results in constriction.  Propranolol’s beta-blocking effects are attributable to its S(-) enantiomer.</p>
<p><span class="Underline">Pharmacodynamic drug interactions</span></p>
<p><span class="Italics">Alpha blockers:</span> Co-administration of beta-blockers with alpha blockers (prazosin) has been associated with prolongation of first dose <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Italics">Antidepressants</span>: The hypotensive effect of MAO inhibitors and tricyclic antidepressants is exacerbated when administered with beta-blockers. </p>
<p><span class="Italics">Nonsteroidal anti-inflammatory drugs</span>:  Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-adrenoreceptor blocking agents. Monitor blood pressure.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_3ba7e966-b68d-427a-9bbe-366db6391c82"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Adults</span></p>
<p><span class="Italics">Absorption: </span>Propranolol is almost completely absorbed after oral administration. However, it undergoes an extensive first-pass metabolism by the liver and on average; only about 25% of propranolol reaches the systemic circulation. Peak plasma concentrations occur about 1 to 4 hours after an oral dose. Administration of protein-rich foods increases the bioavailability of propranolol by about 50% with no change in time to peak concentration.</p>
<p>Propranolol is a substrate for the intestinal efflux transporter, P-glycoprotein (P-gp). However, studies suggest that P-gp is not dose-limiting for intestinal absorption of propranolol in the usual therapeutic dose range.</p>
<p><span class="Italics">Distribution: </span>Approximately 90% of circulating propranolol is bound to plasma proteins (albumin and alpha1 acid glycoprotein). The volume of distribution of propranolol is approximately 4 L/kg. Propranolol crosses the blood-brain barrier and the placenta, and is distributed into breast milk.</p>
<p>Propranolol is extensively metabolized with most metabolites appearing in the urine.</p>
<p><span class="Italics">Metabolism: </span>Propranolol is metabolized through three primary routes: aromatic hydroxylation (mainly 4-hydroxylation), N-dealkylation followed by further side-chain oxidation, and direct glucuronidation. The percentage contributions of these routes to total metabolism are 42%, 41% and 17%, respectively, but with considerable variability between individuals. The four major final metabolites are propranolol glucuronide, naphthyloxylactic acid and glucuronic acid, and sulfate conjugates of 4-hydroxy propranolol. In vitro studies indicated that CYP2D6 (aromatic hydroxylation), CYP1A2 (chain oxidation) and to a less extent CYP2C19 were involved in propranolol metabolism.</p>
<p>In healthy subjects, no difference was observed between CYP2D6 extensive metabolizers (EMs) and poor metabolizers (PMs) with respect to oral clearance or elimination half-life. </p>
<p><span class="Italics">Elimination:</span>The plasma half-life of propranolol ranges from 3 to 6 hours. Less than 1% of a dose is excreted as unchanged drug in the urine. </p>
<p><span class="Underline">Infants</span></p>
<p>The pharmacokinetics of propranolol and 4-OH-propranolol were evaluated in a multiple dose 12 week study conducted in 23 male and female infants 35 to 150 days of age with <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span>. The infants were stratified by age (35 to 90 days and 91 to 150 days). The starting dose was 1.2 mg/kg/day which was titrated to the target dose of 3.4 mg/kg/day in 1.1 mg/kg/day increments at weekly intervals. At steady state, following administration of 3.4 mg/kg/day twice daily, peak plasma propranolol concentrations were observed within 2 hours of oral administration. Clearance of propranolol in infants was similar across the age range studied (2.7 (SD=0.03) L/h/kg in infants &lt;90 days of age and 3.3 (SD=0.35) L/h/kg in infants &gt;90 days of age) and to that in adults when adjusted by body weight. The median elimination half-life of propranolol was about 3.5 hours. Plasma propranolol concentrations approximate a dose proportional increase in the dose range of 1.2 mg/kg/day to 3.4 mg/kg/day. </p>
<p>Plasma concentration of 4-OH-propranolol, the main metabolite, was about 5% of total plasma exposure of propranolol.</p>
<p><span class="Underline">Sex</span></p>
<p>There is no known <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> of pharmacokinetics of propranolol by sex in infants.</p>
<p><span class="Underline">Race</span></p>
<p>There is little information on <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> of pharmacokinetics of propranolol by race in infants.</p>
<p>A study conducted in 12 Caucasian and 13 African-American adult male subjects taking propranolol, showed that at steady state, the clearance of R(+)- and S(-)-propranolol were about 76% and 53% higher in African-Americans than in Caucasians, respectively.</p>
<p>Chinese adult subjects had a greater proportion (18% to 45% higher) of unbound propranolol in plasma compared to Caucasians, which was associated with a lower plasma concentration of alpha1 acid glycoprotein.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_0d02b610-17c2-4155-bb07-ffe36ab22cc3"></a><a name="section-11.4"></a><p></p>
<h2>12.6 Drug Interactions</h2>
<p class="First"><span class="Italics">Impact of propranolol on co-administered drugs: </span>The effect of propranolol on plasma concentration of co-administered drug is presented in the table below.</p>
<p><span class="Bold">Table 3. Effect of propranolol on co-administered drugs</span></p>
<table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Co-administered drug</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Effect on plasma concentration of co-administered drug</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Amide anesthetics (lidocaine, bupivacaine, mepivacaine)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Warfarin</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Propafenone</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase &gt; 200 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Nifedipine</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase  80 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Verapamil</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Pravastatin, lovastatin</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Decrease  20%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Fluvastatin</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Zolmitriptan</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase  60 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Rizatriptan</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase  80 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Thioridazine</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase  370 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Diazepam</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Oxazepam, triazolam, lorazepam, alprazolam</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No change</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Theophylline </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase 70 %</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Impact of co-administered drugs on propranolol: </span>The effect of co-administered drugs on propranolol plasma concentration is presented in the table below.</p>
<p><span class="Bold">Table 4. Effect of co-administered drugs on propranolol</span></p>
<table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Co-administered drug</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Effect on propranolol plasma concentration</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">CYP2D6, CYP1A2 or CYP2C19 inhibitors</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">CYP1A2 or CYP2C19 inducers</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Decrease</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Quinidine</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase &gt; 200 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Nisoldipine</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase  50 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Nicardipine</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase  80 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Chlorpromazine</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase  70 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Cimetidine</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase  50 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Cholestyramine, colestipol</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Decrease  50 %</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Alcohol</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase (acute use), decrease (chronic use)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Diazepam</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Verapamil</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Metoclopramide</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Ranitidine</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Lansoprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Omeprazole</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Propafenone</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase  200 %</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Aluminum hydroxide</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Decrease  50 %</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_ab1b912b-ac03-41b2-96e0-980cb4647b8f"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">13   NONCLINICAL TOXICOLOGY</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_017f0e76-fe97-4221-a767-e34efb4658e9"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First">In studies of mice and rats fed propranolol hydrochloride for up to 18 months at doses of up to 150 mg/kg/day, there was no evidence of drug-related tumorigenesis. On a body surface area basis, this dose in the mouse and rat is about 3 and 7 times, respectively, the MRHD of 3.4 mg/kg/day propranolol hydrochloride in children.</p>
<p>Based on differing results from bacterial reverse mutation (Ames) tests performed by different laboratories, there is equivocal evidence for mutagenicity in one <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> (<span class="Italics">S. typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA 1538).</p>
<p>In a study in which both male and female rats were exposed to propranolol hydrochloride via diet at concentrations of up to 0.05% (about 50 mg/kg or less than the MRHD of 640 mg propranolol hydrochloride in adults) started from 60 days prior to mating and throughout pregnancy and lactation for two generations, there were no effects on fertility. The potential effects of propranolol hydrochloride on fertility of juvenile rats were evaluated following daily oral administration from post-natal Day 4 (PND 4) to PND 21 at dose-levels of 0, 11.4, 22.8 or 45.6  mg/kg/day. No propranolol related effects on reproductive parameters or reproductive development were observed up to the highest dose level of 45.6 mg/kg/day, a dose that represents a systemic exposure of 3 times that seen in children at the MRHD.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="LINK_632b9231-a43b-429a-9158-a21dccb2ee85"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">This study in juvenile rats with propranolol hydrochloride described above was intended to cover the period of development corresponding to infancy, childhood and adolescence. Neurologic effects including <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span> and delayed air righting reflex, increased germinal centers of lymph nodes, and increased white blood cells and <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> were seen at a propranolol hydrochloride dose 45.6 mg/kg/day that represents a systemic exposure of 3 times that seen in children at the MRHD.  Body weights were transiently decreased, and transient decreases in urine volume were associated with higher incidences of minimal <span class="product-label-link" type="condition" conceptid="196813" conceptname="Simple renal cyst">renal cysts</span> and dilation of kidney tubules at doses about equal to the MRHD in children. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_cc520742-f1bb-4b89-9c6f-e500e1fefc2c"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">14   CLINICAL STUDIES</span></h1>
<p class="First">A randomized, double-blind study in 460 infants, aged 35 days to 5 months at inclusion, with proliferating infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> (IH) requiring systemic therapy (excluding life-threatening IH, function-threatening IH, and ulcerated IH with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and lack of response to simple <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> care measures) compared four regimens of HEMANGEOL (1.2 or 3.4 mg/kg/day in twice daily divided doses for 3 or 6 months; N=99-103 per group) to placebo (N=55). Clinical efficacy was evaluated by counting complete or nearly complete resolution of the target <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span>, which was evaluated by blinded centralized independent assessments of photographs at Week 24 compared to baseline.</p>
<p>Demographic patient characteristics and <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> characteristics were similar among the five regimens. For the whole population, 29% were male, 37% were in the lower age group (35-90 days), and 72% were Caucasian. Overall, 70% had a target <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> on the head, most commonly cheek (13%) and forehead (11%).</p>
<p>The main reason for treatment discontinuation was the treatment inefficacy, which happened in 58% of patients randomized to placebo, 25-30% of patients randomized to HEMANGEOL for 3 months (mainly after the switch to placebo), and 7-9% of patients randomized to HEMANGEOL for 6 months. </p>
<p>Overall, 2 out of 55 patients (4%) in the placebo arm and 61 out of 101 patients (60%) on HEMANGEOL 3.4 mg/kg/day for 6 months had complete or nearly complete resolution of their <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> at Week 24 (p &lt;0.0001). </p>
<p>There were no significant differences in response by age (35-90 days / 91-150 days), sex, or <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> site. There were too few non-Caucasians to assess differences in effects by race. </p>
<p>Of patients on HEMANGEOL 3.4 mg/kg/day for 6 months who were considered successes, 10% required retreatment for recurrence of <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>.</p>
<p>A second uncontrolled study in 23 patients with proliferating IH included function-threatening IH, IH in certain anatomic locations that often leave permanent <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span> or <span class="product-label-link" type="condition" conceptid="4168498" conceptname="Deformity">deformity</span>, large facial IH, smaller IH in exposed areas, severe ulcerated IH, pedunculated IH. Target lesions resolved in 36% of patients by 3 months.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_6ec451f8-f8e2-42c3-806f-890cf8d002f7"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">16   HOW SUPPLIED/STORAGE AND HANDLING</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4c5d4a45-8c3f-42bd-84df-fb2de6dd33af"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">HEMANGEOL is supplied as an oral solution. Each 1 mL contains 4.28 mg propranolol hydrochloride (equivalent to 3.75 mg propranolol). HEMANGEOL is supplied in a carton containing one 120 mL bottle with syringe adapter and one 5 mL oral dosing syringe.</p>
<p>NDC 64370-375-01                 Bottle 120 mL</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_75c0505e-720b-456b-90fd-724303dc1967"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 25ºC (77ºF); excursions permitted from 15º to 30ºC (59º to 86ºF). [See USP Controlled Room Temperature.]  </p>
<p>Do not freeze.</p>
<p>Do not shake the bottle before use.</p>
<p>Dispense in original container with enclosed oral dosing syringe. </p>
<p>The product can be kept for 2 months after first opening.</p>
<p>See instructions for using enclosed oral dosing syringe.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_4733d1df-e587-4abb-9982-2b5e21cc9565"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">17   PATIENT COUNSELING INFORMATION</span></h1>
<p class="First">See FDA-approved patient labeling (Medication Guide and Instructions for Use).</p>
<p><span class="Underline">Patient advice</span></p>
<p>Advise parents or caregivers to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</p>
<p><span class="Underline">Instructions for using oral dosing syringe</span></p>
<p>Instruct parents or caregivers on use of the oral dosing syringe.</p>
<p><span class="Underline">Risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></span></p>
<p>Inform parents or caregivers that there is a risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when HEMANGEOL is given to infants who are not feeding regularly or who are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Instruct them to skip dosing under such conditions. </p>
<p>Instruct parents or caregivers how to recognize the signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Tell them to discontinue HEMANGEOL and call their health care provider immediately or take the child to the emergency room in case of suspected <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. </p>
<p><span class="Underline">Cardiovascular risks</span></p>
<p>Advise parents or caregivers that there is a potential risk for <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, aggravation of pre-existing conduction disorders, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with the use of HEMANGEOL. Instruct them to contact their healthcare provider in case of <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, slow or uneven heart beats, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">peripheral coldness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>.</p>
<p><span class="Underline">Respiratory risks</span></p>
<p>Inform parents or caregivers that HEMANGEOL carries risk of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> or exacerbation of <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span>. Instruct them to contact their healthcare provider or go to the nearest hospital emergency room if their child has breathing problems or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> during treatment with HEMANGEOL.</p>
<p><span class="Underline">Other risks</span></p>
<p>Inform parents or caregivers that changes in sleep patterns may occur during HEMANGEOL therapy.</p>
<p>Ask parents or caregivers to tell you all the medications they are administering to their child including prescription and over the counter medicines, vitamins, and herbal supplements. Ask breastfeeding mothers to tell you all the medications they are currently taking, as these may pass into the milk. </p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="LINK_f430745f-0010-4991-a2f4-243755f5f6a5"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p>HEMANGEOL<span class="Sup">®</span> (he-man je-ohl)</p>
<p>(propranolol hydrochloride oral solution)</p>
<p><span class="Bold">What is the most important information I should know about HEMANGEOL?</span></p>
<p><span class="Bold">HEMANGEOL can cause serious side effects, including:</span></p>
<ul class="Disk"><li>
<span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>)</span>, especially if your child is not taking feedings, or is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. HEMANGEOL may make it more difficult to recognize the signs and symptoms of low blood sugar in your child.</li></ul>
<p><span class="Bold">To help reduce the risk of low blood sugar with HEMANGEOL:</span></p>
<ul class="Disk">
<li>Give HEMANGEOL during or shortly after feeding your child. 
</li>
<li>Feed your child regularly during treatment. Tell your doctor if your child has a poor appetite. 
</li>
<li>If your child is not taking feedings, for example, due to an illness or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, do not give   HEMANGEOL until your child is taking feedings normally again. </li>
</ul>
<p><span class="Bold">If your child has any of the signs or symptoms of low blood sugar listed below during treatment with </span><span class="Bold">HEMANGEOL, stop giving your child HEMANGEOL and call your doctor or go to the nearest emergency room right away.</span></p>
<p><span class="Bold">Signs or symptoms of low blood sugar include:  </span><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>, blue or purple skin color, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span> for no apparent reason, irregular or fast heartbeat, poor feeding, low body temperature, unusual <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, breathing stops for short periods of time, and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>.</p>
<p><span class="Bold">What is HEMANGEOL?</span></p>
<p>HEMANGEOL is a prescription medicine used to treat proliferating infantile <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> that requires treatment with a medicine that spreads throughout the body.</p>
<p><span class="Bold">Who should not take HEMANGEOL?</span></p>
<p><span class="Bold">Do not give HEMANGEOL to your child if your child:</span></p>
<ul class="Disk">
<li>was born prematurely and has not reached the corrected age of 5 weeks 
</li>
<li>weighs less than 4 ½ pounds 
</li>
<li>is allergic to propranolol or any of the other ingredients in HEMANGEOL. See the end of this Medication Guide for a list of ingredients in HEMANGEOL 
</li>
<li>has <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of breathing problems 
</li>
<li>has a heart problem, slow heart rate (less than 80 heart beats per minute), very <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> 
</li>
<li>is at risk for low blood sugar, for example is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or unable to take feedings 
</li>
<li>has high blood pressure caused by a tumor on the adrenal gland, called “pheochromocytoma?</li>
</ul>
<p><span class="Bold">What should I tell my doctor before giving my child HEMANGEOL?</span></p>
<p><span class="Bold">Before you start giving HEMANGEOL to your child,tell your doctor about all of your child’s medical conditions.</span></p>
<p><span class="Bold">Tell your doctor about all of the medicines that your child takes</span>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. HEMANGEOL and some medicines may interact with each other and cause serious side effects. Especially tell your doctor if your child takes a steroid medicine. Taking a steroid medicine during treatment with HEMANGEOL may increase your child’s risk of low blood sugar. </p>
<p><span class="Bold">If you are breastfeeding your child, it is important to tell your doctor about all the medicines you take. </span> Certain medicines may pass to your child through your breast-milk and interact with HEMANGEOL. Your doctor should tell you if you should stop breastfeeding.</p>
<p><span class="Bold">How should I give HEMANGEOL to my child?</span></p>
<p><span class="Bold">Follow the detailed Instructions for Use that come with HEMANGEOL for information about the correct way to prepare and give a dose of HEMANGEOL.</span></p>
<ul class="Disk">
<li>Give HEMANGEOL to your child exactly as your doctor tells you. 
</li>
<li>Your doctor may change the dose until it is right for your child, and as your child’s weight changes. 
</li>
<li>
<span class="Bold">Always give HEMANGEOL </span><span class="Bold">with a feeding or right away after a feeding.</span>
</li>
<li>HEMANGEOL is given 2 times each day, at least 9 hours apart. 
</li>
<li>If your child spits up a dose or if you are not sure your child got all of the medicine, do not give another dose. Wait until the next scheduled dose. </li>
</ul>
<p><span class="Bold">What are the possible side effects of HEMANGEOL?</span></p>
<p>See <span class="Bold">“<a href="#LINK_f430745f-0010-4991-a2f4-243755f5f6a5">What is the most important information I should know about HEMANGEOL?</a>?</span></p>
<p><span class="Bold">HEMANGEOL can cause serious side effects, including:</span></p>
<ul class="Disk">
<li>
<span class="Bold">New or worsening slow</span><span class="Bold"> heart rate (<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>) or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>).</span> Call your doctor if your child has any of these symptoms: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> skin color, slow or uneven heartbeats, arms or legs feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, blue or purple skin color, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. 
</li>
<li>
<span class="Bold">Breathing problems or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>.  </span>HEMANGEOL can cause <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of your child’s airway. Call your doctor or go to the nearest hospital emergency room if your child has breathing problems or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> during treatment with HEMANGEOL. 
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>. </span>HEMANGEOL may increase the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in certain children who have severe problems with the blood vessels in their brain, particularly if your child has a large <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma</span> that affects the face or head.</li>
</ul>
<p><span class="Bold">The most common side effects include:</span> <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problems</span>, worsening <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>These are not all the possible side effects of HEMANGEOL. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store HEMANGEOL?</span></p>
<ul class="Disk">
<li>Store HEMANGEOL at room temperature between 68<span class="Sup">o</span> F to 77<span class="Sup">o </span>F (20<span class="Sup">o</span> C to 25<span class="Sup">o</span> C). Do not freeze.  Do not shake before use. 
</li>
<li>Safely throw away any opened bottle of HEMANGEOL after 2 months, even if there is medicine left in the bottle.</li>
</ul>
<p><span class="Bold">Keep HEMANGEOL and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of HEMANGEOL.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or doctor for information about HEMANGEOL that is written for health professionals. Do not use HEMANGEOL for a condition for which it was not prescribed. Do not give HEMANGEOL to other people, even if they have the same symptoms your child has. It may harm them.</p>
<p><span class="Bold">What are the ingredients in HEMANGEOL?</span></p>
<p><span class="Bold">Active ingredient: </span>propranolol hydrochloride</p>
<p><span class="Bold">Inactive ingredients: </span>strawberry flavor, vanilla flavor, hydroxyethylcellulose, saccharin sodium, citric acid monohydrate, and water.</p>
<p>Manufactured for: Pierre Fabre Pharmaceuticals, Inc., Parsippany, NJ 07054</p>
<p>For more information, call 1-855-PFPHARM (737-4276)</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration                                 Issued: Jan 2015</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="LINK_cd812288-18ef-49aa-9f3b-336030583f53"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Bold">Instructions for Use</span></span></p>
<p><span class="Bold">HEMANGEOL<span class="Bold"><span class="Sup">®</span></span> (he-man je-ohl)</span></p>
<p><span class="Bold">(propranolol hydrochloride oral solution)</span></p>
<p>Read these Instructions for Use before giving a dose of HEMANGEOL to your child for the first time and each time you get a refill. There may be new information. Your doctor or pharmacist should show you how to correctly measure and give a dose of HEMANGEOL to your child before you give it for the first time.</p>
<p><span class="Bold">Important</span>: <span class="Bold">Read the Medication Guide that comes with HEMANGEOL.</span></p>
<ul class="Disk">
<li>To reduce the risk of your child getting low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>), you must give HEMANGEOL either during a feeding or right away after a feeding. 
</li>
<li><span class="Bold">Do not give a dose of HEMANGEOL if your child is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, is not taking feedings, or is showing signs or symptoms of low blood sugar.  </span></li>
</ul>
<p>When you get HEMANGEOL from your doctor or pharmacist, you will receive a box that contains the supplies needed to give HEMANGEOL to your child, including:</p>
<ul class="Disk">
<li>One glass bottle of HEMANGEOL 
</li>
<li>One 5 mL oral dosing syringe (inside a plastic bag) that is marked to help you correctly measure a dose of HEMANGEOL (<span class="Bold">See Figure A</span>).  If the carton does not contain the oral dosing syringe, ask your pharmacist to give you an oral dosing syringe that can be used to measure HEMANGEOL. </li>
</ul>
<p><span class="Bold">Figure A</span></p>
<p> <img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-2.jpg"></p>
<p><span class="Bold">Preparing to give your child a dose of HEMANGEOL:</span></p>
<p><span class="Bold">Step 1. </span>Place your box of supplies on a clean flat work surface, such as a table.</p>
<p><span class="Bold">Step 2. </span>Remove the HEMANGEOL bottle and oral dosing syringe from the box (<span class="Bold">See Figure A above</span>). <span class="Bold">Do not shake the bottle before use</span>. Keep the box for storage.</p>
<p><span class="Bold">Step 3. </span>Remove the oral dosing syringe from the plastic bag. Safely throw the plastic bag away. The barrel of the syringe has markings in milliliters (mL). Look at the markings on the barrel of the oral dosing syringe and find the mL marking that matches the HEMANGEOL dose in mL prescribed by your doctor (<span class="Bold">See Figure B</span>).</p>
<p><span class="Bold">Figure B</span></p>
<p> <img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-3.jpg"></p>
<p><span class="Bold">Step 4. </span>Open the bottle of HEMANGEOL by pushing down on the plastic cap while turning the cap to the left (<span class="Bold">See Figure C</span>).</p>
<ul class="Disk"><li>Write down on the box the date when you first open the bottle.</li></ul>
<p><span class="Bold">Figure C</span></p>
<p><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-4.jpg"> </p>
<p><span class="Bold">Step 5. </span>Place the bottle on your work surface. Use one hand to hold the bottle upright.Use your other hand to insert the tip of the oral dosing syringe into the syringe adapter at the top of the bottle. Push the plunger all the way down (<span class="Bold">See Figure D</span>).</p>
<ul class="Disk"><li>Do not remove the syringe adapter. If the syringe adapter is missing talk to your pharmacist.</li></ul>
<p><span class="Bold">Figure D</span></p>
<p><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-5.jpg"> </p>
<p><span class="Bold">Step 6: </span>Use one hand to hold the oral dosing syringe in place. With your other hand, turn the bottle upside down. Pull back on the plunger until the top of the plunger lines up with the marking on the barrel of the syringe that matches the dose of HEMANGEOL prescribed by your doctor (<span class="Bold">See Figure E</span>). Your child’s dose may be different than the dose shown in Figure E.</p>
<p><span class="Bold">Figure E</span></p>
<p><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-6.jpg"> </p>
<p><span class="Bold">Step 7:  </span>Check for air bubbles in the oral dosing syringe. If you see air bubbles, push up on the plunger towards the bottle just enough to remove any large air bubbles and then pull back to the measured dose (<span class="Bold">See Figure F</span>).</p>
<p><span class="Bold">Figure F</span></p>
<p><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-7.jpg"> </p>
<p><span class="Bold">Step 8. </span>Turn bottle upright again and place it in on your work surface. Remove the oral dosing syringe from the bottle (<span class="Bold">See</span><span class="Bold"> Figure G</span>). Do not push the plunger in during this step. The syringe adapter should stay attached to the bottle.</p>
<p><span class="Bold">Figure G</span></p>
<p><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-8.jpg"> </p>
<p><span class="Bold">Giving your child a dose of HEMANGEOL:</span></p>
<p><span class="Bold">Step 9. </span>Slowly squirt HEMANGEOL into your child’s mouth after placing the oral dosing syringe against the inside of the cheek (<span class="Bold">See Figure H</span>).</p>
<ul class="Disk"><li>Keep your child in an upright position for a few minutes right after giving a dose of HEMANGEOL. </li></ul>
<p><span class="Bold">Figure H</span></p>
<p><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-9.jpg"> </p>
<ul class="Disk"><li>If needed, you can dilute the dose of HEMANGEOL in a small amount of milk or fruit juice and give it to your child in a baby’s bottle. If your child spits up a dose or if you are not sure your child got all of the medicine, do not give another dose. Wait until the next scheduled dose.</li></ul>
<p><span class="Bold">Step 10. </span>Replace the plastic cap on the bottle. Close the bottle by turning the plastic cap to the right (<span class="Bold">See Figure I</span>).</p>
<p><span class="Bold">Figure I</span></p>
<p><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-10.jpg"> </p>
<p><span class="Bold">Cleaning the oral dosing syringe:</span></p>
<p><span class="Bold">Step 11: </span>Clean the oral dosing syringe after each use by rinsing with clean tap water (<span class="Bold">See Figure J</span>).</p>
<ul class="Disk">
<li>Do not take apart the oral dosing syringe. 
</li>
<li>Do not use any soap or alcohol based product to clean. Wipe the outside dry. 
</li>
<li>Do not put the oral dosing syringe through a sterilizer or dishwasher.</li>
</ul>
<p><span class="Bold">Figure J</span></p>
<p><img alt="Figure J" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-11.jpg"> </p>
<p><span class="Bold">Step 12: </span>Place the bottle and the oral dosing syringe in the box.</p>
<p><span class="Bold">How should I store HEMANGEOL?</span></p>
<ul class="Disk">
<li>When not in use, keep the bottle of HEMANGEOL and the oral dosing syringe in the box it comes in.</li>
<li>Store HEMANGEOL at room temperature, between 68<span class="Sup">o</span> F to 77<span class="Sup">o</span> F (20<span class="Sup">o</span> C to 25<span class="Sup">o</span> C). Do not freeze.</li>
<li>Safely throw away any opened bottle of HEMANGEOL after 2 months, even if there is medicine left in the bottle.</li>
</ul>
<p><span class="Bold">Keep HEMANGEOL and all medicines out of the reach of children.</span></p>
<p><span class="Bold">This Instructions for Use has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Manufactured for: </p>
<p>Pierre Fabre Pharmaceuticals, Inc.</p>
<p>Parsippany, NJ 07054</p>
<p>Made in France</p>
<p>Issued: May 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_5f3eb379-7762-44b8-991b-34cfd8b01f48"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><br></span></p>
<p><span class="Bold"><img alt="120 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-12.jpg"></span></p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL - 120 mL Bottle Label  </span></p>
<p>NDC 64370-375-01</p>
<p><span class="Bold">Hemangeol<span class="Bold"><span class="Sup">®</span></span></span></p>
<p>(propranolol hydrochloride)</p>
<p><span class="Bold">4.28 mg/mL</span></p>
<p>Dispense with enclosed Medication Guide</p>
<p>Rx only</p>
<p>120 mL</p>
<p><img alt="120 mL Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a&amp;name=hemangeol-13.jpg"><br> </p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL - 120 mL Carton Label </span></p>
<p>NDC 64370-375-01</p>
<p><span class="Bold">Hemangeol<span class="Bold"><span class="Sup">®</span></span></span></p>
<p>(propranolol hydrochloride)</p>
<p><span class="Bold">4.28 mg/mL</span></p>
<p>Dispense with enclosed Medication Guide</p>
<p>Rx only</p>
<p>120 mL</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HEMANGEOL 		
					</strong><br><span class="contentTableReg">propranolol hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64370-375</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROPRANOLOL HYDROCHLORIDE</strong> (PROPRANOLOL) </td>
<td class="formItem">PROPRANOLOL HYDROCHLORIDE</td>
<td class="formItem">4.28 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">VANILLA, STRAWBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64370-375-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">120 mL in 1 BOTTLE, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64370-375-50</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 BOTTLE, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205410</td>
<td class="formItem">04/14/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pierre Fabre Pharmaceuticals, Inc.
							(968997101)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6e5e1e42-a28e-4ded-a67a-54a324667772</div>
<div>Set id: b6f9dd2a-632b-87eb-70f0-b2064d7ed48a</div>
<div>Version: 9</div>
<div>Effective Time: 20150105</div>
</div>
</div> <div class="DistributorName">Pierre Fabre Pharmaceuticals, Inc.</div></p>
</body></html>
